# Xtrackers MSCI Europe Health Care Screened UCITS ETF-1C- Capitalisation (XSDR)

**Page:** https://fundology.uk/fund/xsdr · ISIN LU0292103222

## At a glance

> Capital at risk. Past performance is not a guide to future returns. The value of investments can fall as well as rise.

As of 13/11/2026, XSDR (Xtrackers MSCI Europe Health Care Screened UCITS ETF-1C- Capitalisation, ISIN LU0292103222) closed at £214.45 on the London Stock Exchange. Its ongoing charge is 0.20% a year (about £20 on £10,000). Over the five years to 13/11/2026 its total return was +27.4%, or −0.6% after UK CPIH inflation.

## Summary

Xtrackers SICAV - Xtrackers MSCI Europe Health Care Screened UCITS ETF-1C- Capitalisation is an exchange-traded fund (ETF) from Xtrackers, launched in 2007. It tracks the MSCI Europe Health Care ESG Screened 20-35 Index - EUR — large and medium-sized European companies. You buy and sell it through a share-dealing account or platform during stock-market hours, like a share. Its ongoing charge is 0.2% a year — about £20 a year on every £10,000 invested, taken from the fund's value rather than billed to you. Income from its investments is reinvested inside the fund, so it shows up as a rising price rather than cash paid to you.

Latest close: **£214.45** (13/11/2026).

## Key facts

| Fact | Value |
|---|---|
| Ticker (LSE) | XSDR |
| ISIN | LU0292103222 |
| Also listed as | DXSE (Xetra, euros) |
| Category | Healthcare |
| Type | ETF |
| Provider | Xtrackers |
| Tracks | MSCI Europe Health Care ESG Screened 20-35 Index - EUR |
| Income | Accumulating |
| Ongoing charge | 0.20% a year (£20 per £10,000) |
| Fund size | £303m |
| Launched | 2007 |
| Domicile | Luxembourg |
| UK reporting fund status | Yes — on HMRC’s list of reporting funds (list of 02/11/2026); reporting fund since 01/01/2011 |

## Past returns (periods to 13/11/2026)

After the fund's ongoing charges. "Income reinvested" is total return; "price only" leaves out income paid out. Real returns are after UK CPIH inflation.

| Window | Return | After CPIH inflation | Measured as |
|---|---|---|---|
| 1 year | +10.25% | +6.35% | income reinvested |
| 3 years | +24.05% | +12.08% | income reinvested |
| 5 years | +27.40% | -0.56% | income reinvested |

Returns: as reported (delayed data). Inflation: UK CPIH, latest month published.

## Calendar-year returns

Calendar-year returns of Xtrackers SICAV - Xtrackers MSCI Europe Health Care Screened UCITS ETF-1C- Capitalisation in pounds (price, with income reinvested in the fund): 2022 +0.3%, 2023 +6.9%, 2024 +1.1%, 2025 +8.5%; 2026 to 13/11/2026 +9.7%. Returns of Xtrackers SICAV - Xtrackers MSCI Europe Health Care Screened UCITS ETF-1C- Capitalisation in pounds (price, with income reinvested in the fund) over the 12 months to 30/09/2026: 0.0%; to 30/09/2025: −4.6%; to 30/09/2024: +12.1%; to 30/09/2023: +14.4%; to 30/09/2022: +0.9%.

| Year | Return | After CPIH inflation | Measured as |
|---|---|---|---|
| 2022 | +0.3% | -8.2% | Price |
| 2023 | +6.9% | +2.7% | Price |
| 2024 | +1.1% | -2.4% | Price |
| 2025 | +8.5% | +4.8% | Price |
| 2026 to 13/11/2026 | +9.7% | +6.2% | Price |

## Risk metrics

| Window | Volatility | Max drawdown |
|---|---|---|
| 1 year | 20.61% | -12.16% |
| 3 years | 18.23% | -22.42% |
| 5 years | 17.12% | -22.42% |

## Largest fall

Volatility of Xtrackers SICAV - Xtrackers MSCI Europe Health Care Screened UCITS ETF-1C- Capitalisation in pounds, annualised from weekly returns to 13/11/2026: 20.6% over 1 year, 18.2% over 3 years, 17.1% over 5 years. Largest fall in the price of Xtrackers SICAV - Xtrackers MSCI Europe Health Care Screened UCITS ETF-1C- Capitalisation since November 2021, in pounds: −22.4% from 30/08/2024 to 11/04/2025. The lowest 12-month return of Xtrackers SICAV - Xtrackers MSCI Europe Health Care Screened UCITS ETF-1C- Capitalisation in pounds (price, with income reinvested in the fund) since January 2021 was −19.7% (12 months to 08/08/2025); the highest was +25.1% (12 months to 08/04/2022). On 13/11/2026 the price of Xtrackers SICAV - Xtrackers MSCI Europe Health Care Screened UCITS ETF-1C- Capitalisation was 0.8% below its highest weekly close since November 2021 (30/08/2024), in pounds.

## Charges compared with similar funds

Ongoing charge of Xtrackers SICAV - Xtrackers MSCI Europe Health Care Screened UCITS ETF-1C- Capitalisation 0.20% a year. Compared on 14/11/2026, 19 of the 28 other healthcare funds charge more, 1 the same and 8 less (share classes counted once).

## Charges & eligibility

- Ongoing charges figure (OCF): **0.20%** per year
- Stocks and shares ISA eligible: usually (check with your platform)
- SIPP eligible: usually (check with your provider)
- ISA and SIPP mean the kind of product usually qualifies under HMRC rules. We do not check each platform’s list — each provider decides which funds it offers. Crypto ETNs have not qualified for a stocks and shares ISA since 06/04/2026, and overseas funds that are not UK-recognised UCITS, such as Swiss ETFs, do not usually qualify.

## What it holds

As of 15/11/2026, XSDR holds 45 positions, according to its published holdings. The largest is Roche at 17.33% of the fund; the ten largest make up 75.6%.

### Top holdings

Largest positions (as of 15/11/2026), as a percentage of the whole fund:

| # | Holding | Ticker | Weight |
|---|---|---|---|
| 1 | Roche | [RO](https://fundology.uk/stock/RO) | 17.33% |
| 2 | Novartis | [NOVN](https://fundology.uk/stock/NOVN) | 14.92% |
| 3 | AstraZeneca | [AZN](https://fundology.uk/stock/AZN) | 14.13% |
| 4 | Novo Nordisk · Class B | [NOVO_B](https://fundology.uk/stock/NOVO_B) | 6.66% |
| 5 | Sanofi | [SAN](https://fundology.uk/stock/EURONEXT:SAN) | 5.39% |
| 6 | GSK | [GSK](https://fundology.uk/stock/GSK) | 5.16% |
| 7 | Bayer | [BAYN](https://fundology.uk/stock/BAYN) | 3.12% |
| 8 | argenx | [ARGX](https://fundology.uk/stock/ARGX) | 3.11% |
| 9 | EssilorLuxottica | [EL](https://fundology.uk/stock/EL) | 2.93% |
| 10 | Lonza Group | [LONN](https://fundology.uk/stock/LONN) | 2.84% |

## Where it invests

Shares of the whole fund. Bonds, cash and positions without a classification are shown as they come, not guessed.

### By sector

Added up from the fund’s published holdings, as of 15/11/2026.

| Sector | Weight |
|---|---|
| Health Care | 99.7% |
| Other funds | 0.2% |

### By country

Added up from the fund’s published holdings, as of 15/11/2026.

| Country | Weight |
|---|---|
| Switzerland | 43.5% |
| United Kingdom | 21.9% |
| France | 9.5% |
| Denmark | 8.9% |
| Germany | 7.1% |
| Netherlands | 4.8% |
| Belgium | 2.3% |
| Finland | 0.6% |
| Other countries | 1.3% |

### By type of asset

Added up from the fund’s published holdings, as of 15/11/2026.

| Type of asset | Weight |
|---|---|
| Equity | 99.7% |
| Cash and money market | 0.3% |

The 43 holdings on record (of 45 reported): https://fundology.uk/fund/xsdr/holdings

## Questions people ask

**What is the ongoing charge of XSDR?**

The ongoing charge of XSDR is 0.20% a year — about £20 a year on every £10,000 invested, taken from the fund’s value rather than billed to you. Platform and dealing fees are charged separately. Ongoing charge of Xtrackers SICAV - Xtrackers MSCI Europe Health Care Screened UCITS ETF-1C- Capitalisation 0.20% a year. Compared on 14/11/2026, 19 of the 28 other healthcare funds charge more, 1 the same and 8 less (share classes counted once).

**What does XSDR track?**

XSDR tracks the MSCI Europe Health Care ESG Screened 20-35 Index - EUR — large and medium-sized European companies.

**Is XSDR accumulating or distributing?**

XSDR is accumulating: income is reinvested inside the fund, so it shows up as a rising price rather than cash paid to you.

**What is the ISIN of XSDR?**

The ISIN of XSDR is LU0292103222. An ISIN identifies one exact share class of a fund; XSDR is its ticker on the London Stock Exchange. The same share class is also listed as DXSE (Xetra, euros).

**What does XSDR hold?**

As of 15/11/2026, XSDR holds 45 positions, according to its published holdings. The largest is Roche at 17.33% of the fund; the ten largest make up 75.6%. Its ten largest holdings are Roche (17.33%), Novartis (14.92%), AstraZeneca (14.13%), Novo Nordisk · Class B (6.66%), Sanofi (5.39%), GSK (5.16%), Bayer (3.12%), argenx (3.11%), EssilorLuxottica (2.93%) and Lonza Group (2.84%).

**What were XSDR’s returns in each of the last five years?**

Calendar-year returns of XSDR in pounds (price, with income reinvested in the fund): 2022 +0.3%, 2023 +6.9%, 2024 +1.1%, 2025 +8.5%; 2026 to 13/11/2026 +9.7%. Past performance is not a guide to future returns.

**How has XSDR done after inflation?**

Over the five years to 13/11/2026 XSDR’s total return was +27.4%, or −0.6% after UK CPIH inflation. Past performance is not a guide to future returns.

## Fund documents

- [Fund page at Xtrackers (DWS)](https://etf.dws.com/en-gb/LU0292103222-msci-europe-health-care-ucits-etf-1c/)
- Links checked 12/10/2026.

---

We show information. We are not financial advisers, not authorised by the FCA, and never recommend specific investments.

Capital at risk. Past performance is not a guide to future returns. The value of investments can fall as well as rise.